• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Study shows fewer out-of-target blood glucose levels using Ascensia’s monitoring system

May 2, 2022 By Sean Whooley

Ascensia DiabetesAscensia Diabetes Care announced today that a new study demonstrates reduced out-of-target blood glucose ranges with its Contour system.

The company, which distributes Senseonics’ Eversense continuous glucose monitor (CGM), develops the Contour blood glucose monitoring (BGM) systems and the Contour diabetes app (CDA) for people with diabetes who are managing their blood glucose levels.

According to a news release, the new study — presented at the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) 2022 in Barcelona — showed that people who used the connected Contour BGM systems and app for at least six months can see a reduced frequency of hypoglycemic and hyperglycemic blood glucose readings (BGRs). Ascensia said the data suggests the key benefit of using the systems to avoid out-of-target blood glucose ranges that can lead to serious health complications.

The study assessed data from 7,047 Contour system users in Australia. After six months, the estimated frequency of BGRs in high and very high ranges of people using the system fell by more than 6.5 times and 5.6 times, respectively, compared to baseline.

Ascensia said the decrease was more prominent among users who reported the use of oral antidiabetic medications. Decrease of BGRs in the low range was modest at 1.2 times in the entire study population and registered at 1.38 times in Contour users who were treated with insulin and are more prone to hypoglycemic events.

The majority of those assessed had type 2 diabetes (66.9%).

“We’re pleased to see results from the study showcasing that our CDA system is helping people with diabetes to manage their condition,” Ascensia Head of BGM Marketing and Strategy Frank Held said in the release. “While many diabetes apps support people with diabetes in managing their condition, they don’t all provide alerts or guidance for hypoglycaemic or hyperglycaemic events, like the Contour diabetes app does. Failure to properly address these events can result in serious health complications, so it is crucial that monitoring systems and connected apps facilitate the detection of high and low blood glucose levels.”

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring Tagged With: Ascensia Diabetes Care

IN CASE YOU MISSED IT

  • BD, Mitsubishi Gas Chemical partner on better materials for plastic syringes
  • ApiJect picks up $111M investment from Royalty Pharma, Jefferies
  • FDA approves IND for Ananda Scientific’s PTSD treatment with liquid structure delivery tech
  • Medtronic’s Resolute Onyx drug-eluting stent demonstrates strong safety, efficacy
  • Jabil launches Qfinity reusable auto-injector

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Souring
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS